Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 8/20 | 0.52 |
| ▸ | CTSL | P07711 | 7/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSB | P07858 | 5/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16059278 | 1.00 | ATM (0.53) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL22370935 | 1.00 | ATM (0.53) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL17596414 | 0.88 | CTSS (0.59) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL17596415 | 0.88 | CTSS (0.59) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL30729578 | 0.86 | CTSK (0.49) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL23791954 | 0.86 | TRPM8 (0.55) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL2725000 | 0.86 | SYK (0.71) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL2723152 | 0.86 | SYK (0.71) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL2723154 | 0.86 | SYK (0.71) | ATMELANEPRTN3CTSSCTSL | |
| SCHEMBL13489691 | 0.84 | ATM (0.57) | ATMELANEPRTN3CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10927120-B2 | CDK inhibitors | GI Therapeutics, Inc. (NC) | 2021-02-23 | — | — | US | disclosed |
| US-20200277300-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-2967050-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144740-A2 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ATM 415/4885ELANE 4040/4885PRTN3 2320/4885 |
| US-20200277300-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ATM 415/4885ELANE 4040/4885PRTN3 2320/4885 |
| US-10927120-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | ATM 415/4885ELANE 4040/4885PRTN3 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.